Your essential biotech, medtech, and pharma recap — no noise, just what matters.

Tuesday, September 8, 2026

⚡ Executive Takeaway

The last four days quietly repriced an entire way of picking targets. Lp(a) was the cleanest causal story in cardiovascular genetics, and IL-6 sat at the center of the inflammation hypothesis. Both drugs did exactly what they were designed to do to their biomarkers, and neither program survived contact with outcomes data intact. That is not two drug failures. That is the market being reminded that a surrogate is a hypothesis, not an asset.

Note what both sponsors did next, because it extends a tool we published Friday: neither printed a number. We wrote that a withheld number after a win is a second catalyst you have not been charged for. The mirror image now has two exhibits in one week: a withheld number after a miss is a debt, and it comes due at a congress where the sponsor no longer controls the framing. This week's through line is the surrogate discount: for every asset priced on biomarker movement, ask what the outcomes test is, when it reads, and who pays for the gap in between. We run the tally Friday. 👉 Read Full Analysis

🫀 Cardiovascular

Pelacarsen lowered Lp(a), and it did not matter. NVS | IONS | RPRX

Novartis said Friday that Lp(a)HORIZON, an 8,323 patient outcomes trial in patients with elevated Lp(a) and established cardiovascular disease, missed its primary composite of cardiovascular death, non fatal heart attack, non fatal stroke, and urgent coronary revascularization. Lp(a) lowering was achieved, but the company disclosed no hazard ratio, no p value, and no reduction percentage; the data go to a future congress. This was the first large outcomes test of the most genetically convincing unvalidated target in cardiology, and every other Lp(a) program, including Amgen's olpasiran and Lilly's lepodisiran, now runs its ongoing outcomes trial under a failed precedent. NVS closed down 1.9% Friday; market data, no cause assigned.

🧪 Inflammation

The IL-6 heart bet is down to one trial. NVO

Novo Nordisk confirmed to press Monday that it stopped the HERMES and ATHENA Phase 3 heart failure trials of ziltivekimab early, after the data monitoring committee reviewed the totality of the data and saw a low likelihood of a different outcome from ZEUS, the outcomes trial that missed its primary endpoint in July. Fierce Biotech puts the stopped trials at roughly 4,900 and 673 patients with heart failure with mildly reduced or preserved ejection fraction; there is no company press release as of Monday night, so the details rest on reporting plus company statements. Only ARTEMIS, in patients after an acute heart attack, continues toward an expected first half 2027 readout.

🧬 Rare Disease

A 54 patient approval and an 8,323 patient failure landed on the same company three days apart. IONS

The FDA granted standard approval to Zanvastro (zilganersen), Ionis' antisense drug and the first disease modifying treatment for Alexander disease, dosed 50 mg quarterly by intrathecal injection, on a pivotal trial showing a 33.3% gait speed benefit (p=0.041) in patients five and older. A rare pediatric disease priority review voucher came with it, the list price is not yet disclosed, and Recordati holds ex US rights. Then the partnered Lp(a) program failed on Friday. IONS closed the week essentially flat, down 0.1%, which is what a portfolio pricing a full approval and a partnered outcomes failure at once looks like.

📏 Obesity

40.4% of children on semaglutide finished below the obesity threshold. Zero placebo children did. NVO

STEP Young enrolled 165 children ages 6 to under 12, more than 85% with severe obesity, and ran weight based weekly semaglutide against placebo for 68 weeks with lifestyle intervention in both arms. The primary endpoint of superior BMI reduction was met, and 40.4% versus 0% crossed below the obesity threshold. Novo reported safety consistent with prior pediatric and adult trials and no concerns for growth or pubertal development. Full data land at ObesityWeek, November 14 to 17; the study was run under semaglutide's post marketing pediatric requirements, and the same sponsor released it on the day its cardiovascular inflammation program shrank to one trial.

💰 Deals

Menarini paid EUR 62M upfront for a once every two weeks GLP-1, and the math rhymes. Menarini is private; Gan & Lee trades in Shanghai, no US close

Menarini licensed bofanglutide (GZR18), Gan & Lee's long acting GLP-1 receptor agonist dosed once every two weeks, across 39 European countries for EUR 62M upfront and up to EUR 726M total excluding royalties, with double digit royalties separate: standard construction, ledger eligible, entry #14. The cash share is 8.5%, the same as GSK's Hutchmed KRAS deal from the same week. One asset is preclinical, the other has met primaries in Chinese Phase 3 and US Phase 2 trials; the Pro brief takes apart what the same share at opposite ends of the risk curve is actually measuring. Some coverage quotes $771M; that is a dollar conversion of the euro total.

🩻 Medtech

Boston Scientific's good news arrived with 1,081 injuries attached. BSX

The company's September 4 update said shipping has begun for the majority of products at major global distribution centers and electronic ordering is restored, with growing confidence the unauthorized access was limited to select internal facing IT infrastructure; there is still no timeline for full restoration and no quantified impact. Separately, an FDA alert dated September 3 covered the removal of Infinion CX spinal cord stimulator leads tied to 1,081 serious injuries and no deaths as of May 27, from mechanical stress at the anchor site that can fracture leads; the removal began with a June 17 customer letter, and the FDA classifies it as its most serious recall type. The two events are unrelated, but they now share a ticker and a month. BSX rose 1.8% Friday; market data, no cause assigned.

📋 Quick Hits

📖 In Today's Full Analysis

Be sure to read the full article for all the details, including:

👉 Read the full breakdown →

Markets reopen this morning with four days of news priced into nothing, and the first tape of a short week is usually the honest one. The through line is set: by Friday we will know what the surrogate discount costs. What are you watching? Reply to this email.

Sponsorship slots for 2026 are limited. See packages and pricing →

NEW: BioMed Nexus Signals, weekly sales intelligence for life sciences BD teams. Learn more →